<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:02:41Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7553965" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7553965</identifier>
        <datestamp>2021-07-06</datestamp>
        <setSpec>brjcancer</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="brief-report" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Cancer</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-0920</issn>
              <issn pub-type="epub">1532-1827</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7553965</article-id>
              <article-id pub-id-type="pmcid">PMC7553965</article-id>
              <article-id pub-id-type="pmc-uid">7553965</article-id>
              <article-id pub-id-type="pmid">32624575</article-id>
              <article-id pub-id-type="pmid">32624575</article-id>
              <article-id pub-id-type="publisher-id">958</article-id>
              <article-id pub-id-type="doi">10.1038/s41416-020-0958-8</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Comment</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yuan</surname>
                    <given-names>Chen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Ng</surname>
                    <given-names>Kimmie</given-names>
                  </name>
                  <address>
                    <email>kimme_ng@dfci.harvard.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Department of Medical Oncology, </institution><institution>Dana-Farber Cancer Institute and Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>6</day>
                <month>7</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>13</day>
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <volume>123</volume>
              <issue>8</issue>
              <fpage>1205</fpage>
              <lpage>1206</lpage>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>2</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>26</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>9</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Cancer Research UK 2020</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Note</bold> This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Preclinical and epidemiological evidence suggests that vitamin D may have anti-cancer activities in patients with colorectal cancer. A recently completed, randomised Phase 2 trial of vitamin D<sub>3</sub> supplementation in patients with metastatic colorectal cancer has shown promising results, and a Phase 3 trial is currently underway.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Colorectal cancer</kwd>
                <kwd>Translational research</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>C.Y. and K.N. are supported by the Pussycat Foundation Helen Gurley Brown Presidential Initiative.</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                      <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P50CA127003, R01CA205406, and R01CA118553</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Ng</surname>
                      <given-names>Kimmie</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>The SUNSHINE clinical trial was additionally supported by Gloria Spivak Faculty Advancement Award; Friends of Dana-Farber Cancer Institute Award; Project P Fund; Consano; Pharmavite; and Genentech. C.Y. and K.N. are supported by the Pussycat Foundation Helen Gurley Brown Presidential Initiative.</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Cancer Research UK 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Main</title>
              <p id="Par2">Colorectal cancer (CRC) is the third most common cancer in both men and women in the United States.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> It is also the second leading cause of cancer death in the United States,<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> as well as worldwide.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, ~21% of CRC patients have metastatic disease with a 5-year survival rate of only 14%.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Therefore, novel treatment approaches that are safe, can delay progression, and prolong survival are urgently needed for this group of patients.</p>
              <p id="Par3">Vitamin D is an inexpensive, non-toxic, and easily accessible treatment that has demonstrated anti-neoplastic activities against CRC. Colon cancer cells express high levels of the vitamin D receptor (VDR).<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> In vitro studies found that by binding with VDR, vitamin D can induce apoptosis of colon cancer cells and counteract aberrant WNT-β catenin signalling.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> In <italic>APC</italic>(min) mice, a model of intestinal tumorigenesis, tumour burden was increased by inactivation of the <italic>VDR</italic> gene and decreased by treatment with vitamin D or its synthetic analogue.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup></p>
              <p id="Par4">To further explore these findings in CRC patients, observational studies were conducted to evaluate the association between plasma levels of 25-hydroxyvitamin D [25(OH)D] and patient outcome. Prospective cohort studies, with circulating 25(OH)D levels measured either prior to or at cancer diagnosis, consistently showed a high prevalence of vitamin D deficiency among CRC patients.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> Moreover, CRC patients with higher 25(OH)D levels had longer survival times than those with lower levels.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> In the initial report of 304 CRC patients from the Nurses’ Health Study and the Health Professionals Follow-Up Study, subgroup analyses suggested a greater association of 25(OH)D levels with overall survival among patients with stage III or IV disease versus stage I or II.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> However, in such studies that included patients with all stages of CRC, those with metastatic disease accounted for only a small fraction, resulting in inadequate power to evaluate the relationship between 25(OH)D levels and survival for this group of patients.</p>
              <p id="Par5">To date, two large prospective cohort studies have been conducted to specifically evaluate the association of circulating 25(OH)D levels with survival of patients with metastatic CRC.<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup> One was conducted among 515 patients with stage IV CRC enrolled in the North Central Cancer Treatment Group 9741 trial, which found a significant association between higher 25(OH)D levels at diagnosis and improved overall survival among patients receiving FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> A later analysis of 1043 patients with metastatic CRC who were enrolled on Cancer and Leukemia Group B (Alliance)/SWOG 80405, a randomised Phase 3 trial of chemotherapy plus biologicals for first-line treatment,<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> confirmed the association between higher plasma 25(OH)D levels and improved progression-free and overall survival.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup></p>
              <p id="Par6">Although observational studies support a positive association between 25(OH)D levels and survival of patients with metastatic CRC, they are not able to establish a causal role of higher 25(OH)D levels in improving survival. Vitamin D insufficiency can be a surrogate of worse health or a reflection of less favourable disease, which may confound the true relationship between vitamin D and survival. A double-blind Phase 2 randomised clinical trial, SUNSHINE, was therefore conducted to examine whether addition of high-dose vitamin D<sub>3</sub> (4000 IU/day), versus standard-dose vitamin D<sub>3</sub> (400 IU/day), to standard chemotherapy can improve outcomes in patients with metastatic CRC.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> At study baseline, 91% of these patients had insufficient levels (&lt;30 ng/ml) of 25(OH)D, with a median level of 16.1 ng/ml in the high-dose vitamin D<sub>3</sub> group and 18.7 ng/ml in the standard-dose vitamin D<sub>3</sub> group. During supplementation, median plasma 25(OH)D levels increased into the sufficient range (≥30 ng/ml) among patients receiving high-dose vitamin D<sub>3</sub> (median: 35.2 ng/ml), but remained unchanged with standard-dose vitamin D<sub>3</sub> (median: 18.5 ng/ml), supporting the ability of high-dose vitamin D<sub>3</sub> supplementation to raise 25(OH)D levels in patients with metastatic CRC undergoing chemotherapy. Moreover, patients receiving high-dose vitamin D<sub>3</sub> had improved progression-free survival compared with those receiving standard-dose vitamin D<sub>3</sub> (median progression-free survival: 13.0 months versus 11.0 months; stratified log-rank <italic>P</italic> = 0.03), Importantly, high-dose vitamin D<sub>3</sub> supplementation did not result in any added toxicity.</p>
              <p id="Par7">To determine whether vitamin D supplementation should be considered a part of standard treatment of metastatic CRC, a confirmatory multicentre, double-blind, randomised Phase 3 trial of vitamin D<sub>3</sub> supplementation in combination with standard chemotherapy among previously untreated patients with metastatic CRC called SOLARIS is currently underway through the Alliance for Clinical Trials in Oncology (ClinicalTrials.gov identifier: NCT04094688). The trial will enrol 400 patients with a greater diversity in race and geographical residence, as well as adequate power to detect a progression-free and overall survival benefit.</p>
              <p id="Par8">The evolution and development of vitamin D into a potential therapeutic agent for cancer is a prime example of the importance of research on diet and lifestyle factors and the critical role that they may play in cancer pathogenesis and treatment. Repurposing a safe, affordable, and accessible agent such as vitamin D could potentially have a large and wide-reaching impact globally, even in regions with fewer resources. Robust funding and support are therefore needed to conduct further studies on the biological mechanisms underlying the activity of vitamin D and other modifiable factors in CRC, such that their acceptance and incorporation into standard paradigms of patient care and management may be facilitated.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>C.Y. and K.N. both contributed to the writing, revision, and approval of this manuscript.</p>
            </notes>
            <notes id="FPar1">
              <title>Ethics approval and consent to participate</title>
              <p id="Par9">Not applicable.</p>
            </notes>
            <notes id="FPar2">
              <title>Data availability</title>
              <p id="Par10">Not applicable.</p>
            </notes>
            <notes id="FPar3" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par11">K.N. declares research funding from Evergrande Group, Genentech, Gilead Sciences, Pharmavite, Revolution Medicines, Tarrex Biopharma, and Trovagene; advisory board participation for Array Biopharma, Bayer, Eli Lilly and Company, Genentech, and Seattle Genetics; and consulting for Tarrex Biopharma. C.Y. declares no conflicts of interest.</p>
            </notes>
            <notes id="FPar4" notes-type="funding">
              <title>Funding information</title>
              <p id="Par12">The SUNSHINE clinical trial was supported by P50CA127003, R01CA205406, and R01CA118553 from the National Institutes of Health, National Cancer Institute; Gloria Spivak Faculty Advancement Award; Friends of Dana-Farber Cancer Institute Award; Project P Fund; Consano; Pharmavite; and Genentech. C.Y. and K.N. are supported by the Pussycat Foundation Helen Gurley Brown Presidential Initiative.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siegel</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>KD</given-names>
                    </name>
                    <name>
                      <surname>Jemal</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer statistics, 2020</article-title>
                  <source>CA Cancer J. Clin.</source>
                  <year>2020</year>
                  <volume>70</volume>
                  <fpage>7</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>
                  <pub-id pub-id-type="pmid">31912902</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bray</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Ferlay</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Soerjomataram</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Siegel</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Torre</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Jemal</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>
                  <source>CA Cancer J. Clin.</source>
                  <year>2018</year>
                  <volume>68</volume>
                  <fpage>394</fpage>
                  <lpage>424</lpage>
                  <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
                  <pub-id pub-id-type="pmid">30207593</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meggouh</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Lointier</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Saez</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Sex steroid and 1,25-dihydroxyvitamin D<sub>3</sub> receptors in human colorectal adenocarcinoma and normal mucosa</article-title>
                  <source>Cancer Res.</source>
                  <year>1991</year>
                  <volume>51</volume>
                  <fpage>1227</fpage>
                  <lpage>1233</lpage>
                  <?supplied-pmid 1847660?>
                  <pub-id pub-id-type="pmid">1847660</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dou</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Ng</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Giovannucci</surname>
                      <given-names>EL</given-names>
                    </name>
                    <name>
                      <surname>Manson</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Qian</surname>
                      <given-names>ZR</given-names>
                    </name>
                    <name>
                      <surname>Ogino</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence</article-title>
                  <source>Br. J. Nutr.</source>
                  <year>2016</year>
                  <volume>115</volume>
                  <fpage>1643</fpage>
                  <lpage>1660</lpage>
                  <pub-id pub-id-type="doi">10.1017/S0007114516000696</pub-id>
                  <pub-id pub-id-type="pmid">27245104</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maalmi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Walter</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Jansen</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Boakye</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Schottker</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hoffmeister</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association between blood 25-hydroxyvitamin D levels and survival in colorectal cancer patients: an updated systematic review and meta-analysis</article-title>
                  <source>Nutrients</source>
                  <year>2018</year>
                  <volume>10</volume>
                  <fpage>896</fpage>
                  <pub-id pub-id-type="doi">10.3390/nu10070896</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ng</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Meyerhardt</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Feskanich</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hollis</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Giovannucci</surname>
                      <given-names>EL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2008</year>
                  <volume>26</volume>
                  <fpage>2984</fpage>
                  <lpage>2991</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.15.1027</pub-id>
                  <pub-id pub-id-type="pmid">18565885</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yuan</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Sato</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hollis</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Niedzwiecki</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ou</surname>
                      <given-names>FS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma 25-hydroxyvitamin D levels and survival in patients with advanced or metastatic colorectal cancer: findings from CALGB/SWOG 80405 (Alliance)</article-title>
                  <source>Clin. Cancer Res.</source>
                  <year>2019</year>
                  <volume>25</volume>
                  <fpage>7497</fpage>
                  <lpage>7505</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0877</pub-id>
                  <pub-id pub-id-type="pmid">31548349</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ng</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sargent</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Goldberg</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Meyerhardt</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Green</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Pitot</surname>
                      <given-names>HC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <fpage>1599</fpage>
                  <lpage>1606</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.31.7255</pub-id>
                  <pub-id pub-id-type="pmid">21422438</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Venook</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Niedzwiecki</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lenz</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Innocenti</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Fruth</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Meyerhardt</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial</article-title>
                  <source>JAMA</source>
                  <year>2017</year>
                  <volume>317</volume>
                  <fpage>2392</fpage>
                  <lpage>2401</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2017.7105</pub-id>
                  <pub-id pub-id-type="pmid">28632865</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ng</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Nimeiri</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>McCleary</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Abrams</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Yurgelun</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Cleary</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of high-dose vs standard-dose vitamin D<sub>3</sub> supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: The SUNSHINE Randomized Clinical Trial</article-title>
                  <source>JAMA</source>
                  <year>2019</year>
                  <volume>321</volume>
                  <fpage>1370</fpage>
                  <lpage>1379</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2019.2402</pub-id>
                  <pub-id pub-id-type="pmid">30964527</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
